The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.
John P. Neoptolemos, MA, MB, BChir, MD
Advertisement
Articles by John P. Neoptolemos, MA, MB, BChir, MD
Advertisement
Latest Updated Articles
ESPAC-4: Adjuvant Gemcitabine/Capecitabine in Resected Pancreatic CancerPublished: June 14th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research
2
Could Scorpion Venom Component Play a Role in Glioblastoma Management?
3
FDA Approves Abbreviated NDA for Dasatinib Tablets in Leukemia Indications
4
What Were The Most Impactful GU Oncology Data From ESMO 2025?
5
